Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Search results for:

mirvetuximab soravtansine

mirvetuximab soravtansine
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Elahere INJECTION, INTRAVENOUS 5 mg/mL      
Comments:

Restricted to Oncology for use in the outpatient setting. Insurance certification and PAP eligibility will be reviewed for each case before usage, and a plan developed for drug therapy in each case.

Reviewed: Jan. 2023 (Elahere)

 

Spotlight Mirvetuximab Sorvatansine-gynx (Elahere)

Last updated: Mar. 29, 2026
Rhazdrugs mirvetuximab soravtansine






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved